跳到正文
原文
Endpoints News 生物医药· Reynald Castaneda·· 2 天前AI 评分33

辉瑞通过与Starna Therapeutics授权合作进入in vivo CAR-T领域

Pfizer gets into in vivo CAR-T through licensing deal with Starna Therapeutics

AI 导读

辉瑞支付3.3亿美元预付款,获得Starna Therapeutics授权,正式进入in vivo CAR-T领域。该交易授予辉瑞大中华区以外地区的独家权益。

正文

Pfiz­er is en­ter­ing the in vi­vo CAR-T race, pay­ing $330 mil­lion up­front to Star­na Ther­a­peu­tics. The deal gives Pfiz­er ex­clu­sive rights out­side of Greater Chi­na …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news